SCHEMBL31401835

SCHEMBL31401835

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.65
▸ MAPK8 P45983 1/20 0.64
▸ MAPK9 P45984 1/20 0.64
▸ MAPK10 P53779 1/20 0.64
▸ PTH1R Q03431 2/20 0.53
▸ NMUR2 Q9GZQ4 3/20 0.50
▸ NMUR1 Q9HB89 3/20 0.50
▸ VIPR1 P32241 1/20 0.50
▸ VIPR2 P41587 1/20 0.50
▸ KDM1A O60341 1/20 0.50
▸ GLP1R P43220 2/20 0.49
▸ TFPI P10646 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30625038 0.96 KEAP1 (0.62) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL29376487 0.96 KEAP1 (0.62) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL29374226 0.94 KEAP1 (0.59) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL30906548 0.93 KEAP1 (0.72) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL29376375 0.92 KEAP1 (0.60) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL30624804 0.92 MAPK8 (0.58) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL30625028 0.92 MAPK8 (0.58) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL29679527 0.92 MAPK8 (0.66) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL30906447 0.92 KEAP1 (0.66) KEAP1MAPK8MAPK9MAPK10PTH1R
SCHEMBL31688328 0.92 TFPI (0.59) KEAP1MAPK8MAPK9MAPK10NMUR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113286612-B Humanized antibodies against IGF-I receptor 帝人制药株式会社 2024-12-24 — — CN disclosed
Send feedback